Posts by Magali Bischof

Bachem supplies key anaesthetic drug to support fight against COVID-19   The Swiss-based company, Bachem, is the world leader in the development and production of peptide-based active pharmaceutical ingredients.   1 million CHF was invested to increase its production capacity. The team based in Vionnaz, in the canton of Valais, is working 24/7 to produce…

Lonza | A key player in the COVID-19 vaccine production   Lonza, the Valais-based company, has signed a 10 year deal to support Moderna Therapeutics in the production of the new COVID-19 vaccine using the mRNA technology.   While the trials still prove to be successful, Lonza has confirmed its ability to produce hundreds of…

ADC Therapeutics chooses the New York Stock Exchange   On 15 May 2020, the Biopôle-based company, ADC Therapeutics went public. More than 14 million shares went for the price of $19. At the close of trading at the New York Stock Exchange, the share was worth $30, an increase of 57% in value since the…

Partners are taking Jakafi drug into a second late-stage trial for COVID-19 patients on ventilators   On 5 May 2020, Incyte and Novartis announced that phase II clinical trials were entering a second and last stage for the Jakafi drug, also known as ruxolitinib. The drug will further be tested during phase III clinical trial…

Medtronic is publicly sharing design specifications for its ventilators to support the fight against COVID-19   Medtronic is sharing the design specifications for the puritan BennettTM 560 (PB560) to allow innovators, inventors, start-ups, and academic institutions to leverage their own expertise and resources to evaluate options for rapid ventilator manufacturing. In these unprecedented times, innovation…

Adamant Innotech and CSEM develop a simultaneous diagnostic test for past COVID-19, flu and SRAS infections   On 9 April 2020, the Swiss startup Adamant Innotech and the CSEM announced working in collaboration towards the development of a rapid ultra-sensitive serological test able to determine whether an individual has been infected by the SARS-CoV-2 (COVID-19)…

Quotient Limited Announces the Completion of the SARS-CoV-2 Antibody Test Development   Vaud-based Quotient Limited announced on 6 April 20202, the completion of its SARS-CoV-2 antibody test development for the fully automated high throughput MosaiQ system in response to the global COVID-19 pandemic.   The antibody test has a broad range of applications such as…

First rapid COVID-19 serological test to enter Swiss market   On 6 April 2020, Augurix SA and GaDia announce the launch of the first rapid serological test on the Swiss market. The test was co-developed by the Valais-based company and startup in collaboration with their Asian partners.   The co-development is based on the SARS-Cov-1…

Gnubiotics accelerates testing of multivalent-glycan based pipeline candidates against viral entry of COVID-19   Since 2016, Gnubiotics has invested in understanding the science of glycans, specifically their natural properties of selective microbiome modulation. This understanding of glycan structure combined with efficacy data generated on microbial function has prompted Gnubiotics response to join the global fight…

In light of the COVID-19 situation, we are exceptionally posting the information in French on our website. Do not hesitate to get in contact with us if you need any guidance or explanations in English regarding the measures implemented by the Swiss Federal Council and western Switzerland Cantons to support the country’s economy in these…